Nephrogen
Curative genetic medicines for kidney diseases
About
Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies.
Nephrogen's underlying platform combines AI and high-throughput screening to engineer safer, more efficient, and less expensive gene delivery vehicles for reaching the kidney and pancreas, and has attracted non-dilutive funding from seven major pharmaceutical companies including Merck KGaA, Novartis, and Bristol Myers Squibb.
Topics
- Location
- New York, NY, United States
- Team size
- 5 employees
- YC batch
- Summer 2020
- Status
- Active
- Stage
- Early stage
